Patent details

LUC50021 Product Name: Datopotamab déruxtécan

Basic Information

Publication number:
LUC50021
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP148747454
Legal Status:
Pending & Published
Application number:
LUC50021
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/25/1915
Marketing Authorization Type:
Marketing Authorization Date:
08/04/2025
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
12/09/2025
First Marketing Authorization date:
08/04/2025
Grant date:
Activation date:
Publication date:
15/09/2025
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
24/12/2039
SPC Extension Expiration:
24/12/2039
Rejection date:
Withdrawal date:

Owner

From:
12/09/2025
 
 

Name:
Daiichi Sankyo Company, Limited
Address:
3-5-1, Nihonbashi Honcho Chuo-ku, Tokyo 103-8426, Japan (JP)

Name:
Sapporo Medical University
Address:
291-85, Minami 1-jo Nishi 17-chome Chuo-ku, Sapporo-shi, Hokkaido 060-8556, Japan (JP)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
12/09/2025
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

Bulletin Heading:
SPC1
Bulletin edition number:
2025/11
Publication date:
02/10/2025
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:
01/01/2035
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
12/09/2025 Application Form 5
12/09/2025 General Document 11
12/09/2025 Outgoing Correspondence 2
12/09/2025 General Document 3
12/09/2025 General Document 35
12/09/2025 General Document 1
15/09/2025 Outgoing Correspondence 1
15/09/2025 Publication 1